Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Shares Issued (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Shares Issued for 10 consecutive years, with $265359.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued fell 98.01% year-over-year to $265359.0, compared with a TTM value of $265359.0 through Sep 2025, down 98.23%, and an annual FY2024 reading of $15.0 million, up 7399.43% over the prior year.
  • Shares Issued was $265359.0 for Q3 2025 at Kiora Pharmaceuticals, down from $13.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $13.3 million in Q3 2024 and bottomed at -$98500.0 in Q4 2023.
  • Average Shares Issued over 4 years is $3.7 million, with a median of $300000.0 recorded in 2024.
  • The sharpest move saw Shares Issued skyrocketed 20100.0% in 2024, then crashed 98.01% in 2025.
  • Year by year, Shares Issued stood at $9.8 million in 2021, then plummeted by 101.01% to -$98500.0 in 2023, then skyrocketed by 13612.21% to $13.3 million in 2024, then plummeted by 98.01% to $265359.0 in 2025.
  • Business Quant data shows Shares Issued for KPRX at $265359.0 in Q3 2025, $13.3 million in Q3 2024, and $300000.0 in Q2 2024.